Commodore Capital LP Invests $13.85 Million in Replimune Group, Inc. $REPL

Commodore Capital LP bought a new position in shares of Replimune Group, Inc. (NASDAQ:REPL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,425,000 shares of the company’s stock, valued at approximately $13,851,000. Replimune Group comprises approximately 0.9% of Commodore Capital LP’s investment portfolio, making the stock its 27th largest holding. Commodore Capital LP owned approximately 1.73% of Replimune Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC lifted its holdings in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after buying an additional 33,574 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after buying an additional 119,145 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after buying an additional 6,616 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after acquiring an additional 18,263 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on REPL shares. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 price target on the stock in a research report on Friday, May 29th. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Finally, Wedbush raised their target price on Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a research report on Monday, June 1st. Seven analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Replimune Group currently has an average rating of “Reduce” and a consensus price target of $4.88.

Insider Transactions at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Replimune Group Stock Up 13.9%

Shares of NASDAQ:REPL opened at $10.00 on Thursday. The business has a 50-day moving average price of $5.30 and a 200 day moving average price of $7.25. The company has a market capitalization of $825.70 million, a price-to-earnings ratio of -2.91 and a beta of 0.91. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.